Targeting covid-19 with a therapeutic interfering particle
Ended Project Grant Awarded Last action
- Award ID
- R41AI157129
- Recipient
-
Aleph Therapeutics, Inc. UEI PH2KFR4TMT84
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,195,928
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $895,928.00 Federal
- $300,000.00 Non-federal
- Place of performance
- San Francisco, CA 94143, USA
Award details come from USAspending.gov.
Description
- Abstract
- The covid-19 pandemic caused by severe acute respiratory coronavirus 2 (sars-COV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, IT is critical to explore novel strategies to mitigate this crisis. Aleph therapeutics and ucsf have jointly developed ETIP1, a therapeutic interfering particle. ETIP1 was developed under a DARPA-funded program and shows potent broad-spectrum activity across enteroviruses (poliovirus type 1 and 3, EVA71, and coxsackievirus B3) as well as respiratory viruses EV-D68/HRV-87, rhinovirus A16 and A1B, and influenza a. Recently we have shown that ETIP1 significantly inhibits replication of sars-COV-2 both in cell culture and in K18-ACE2 mice. Given these results, IT is critical to thoroughly evaluate ETIP1 as a potential agent against sars-COV-2. This work could be the starting point for a potential therapy or prophylactic agent against sars-COV-2. This would also represent a significant breakthrough for the development of a broad-spectrum antiviral agent that could potentially target current and future viral threats.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $295,928 | $0 | |
| Amendment | $300,000 | $0 | |
| Original award | $300,000 | $300,000 |
Quick answers
Who received award R41AI157129?
R41AI157129 was awarded to Aleph Therapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 5, 2021.
How much is award R41AI157129 worth?
$1,195,928 has been obligated on R41AI157129: $895,928 in federal funding and $300,000 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award